SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01033045

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure

The purpose of this study is to describe the management of patients with chronic hepatitis C and previous treatment failure.

NCT01033045 Hepatitis C
MeSH: Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis
HPO: Hepatitis


Primary Outcomes

Measure: Describe the management of patients with chronic hepatitis C and previous treatment failure

Time: 6 years

Secondary Outcomes

Measure: To know the frequency of the causes for not responding to the previous treatment: lack of adherence to treatment, incomplete dose of antiviral treatment, insufficient treatment duration or treatment resistance.

Time: 6 years

Measure: To assess the percentage of patients with previous treatment failure who are not candidates for re-treatment and its causes.

Time: 6 years

Measure: To evaluate the implementation of current recommendations based on the cause of the previous therapeutic failure, in patients with chronic hepatitis C in whom a new course of the antiviral treatment is decided to be administered.

Time: 6 years

Measure: To know the causes of the dose modifications and withdrawal of treatment during the follow-up period in patients who start re-treatment.

Time: 6 years

Measure: To know the percentage of patients that achieve sustained viral response when implementing the recommendations based on the cause of the previous therapeutic failure.

Time: 6 years

Description: The rs12979860 polymorphism in the gene IL 28B that is located on chromosome 19 showed to be strongly associated with the development of sustained viral response (SVR) in patients with chronic hepatitis C treated with PEG-IFN-α/RBV. Patients with this polymorphism clear the virus more easily.

Measure: To determine the presence of the polymorphism rs12979860 in the gene IL 28B located on chromosome 19.

Time: 6

Measure: Compare the management of patients with chronic hepatitis C prior treatment failure before and after the appearance of new treatments.

Time: 3

Time Perspective: Prospective


There is one SNP

SNPs


1 rs12979860

To determine the presence of the polymorphism rs12979860 in the gene IL 28B located on chromosome 19..

The rs12979860 polymorphism in the gene IL 28B that is located on chromosome 19 showed to be strongly associated with the development of sustained viral response (SVR) in patients with chronic hepatitis C treated with PEG-IFN-α/RBV.



HPO Nodes


HPO:
Hepatitis
Genes 90
CD247 CTNNB1 ATP7B CASP10 PIEZO1 GUSB BLNK SHPK CYP7A1 IL17RA IGF2R CASP8 SH2D1A SLC25A15 BTK BTK C4B CD79B VPS33B XIAP SERPINA1 PIK3R1 GLIS3 POU2AF1 CIITA FOXP3 TPP2 RFX5 CIITA RASGRP1 RFXANK SLC25A15 AXIN1 TCF4 CD3D TP53 IL12A PRKCD CD40LG BTK IGHM IL17RC ALMS1 TRAF3IP2 KRT8 FAS LRRC8A FAS IL17F XIAP SPIB C1S RFX5 RFXAP MST1 TTC7A COG8 SKIV2L VIPAS39 IGLL1 PDGFRL TNFSF15 HSD3B7 CD3E AMACR ATP7B FASLG RFXANK IL12RB1 TCF3 CD79A KRT18 IRF5 MET PIK3CA MMEL1 ITCH TBX19 IL21R AIRE RFXAP TTC7A CLEC7A GPR35 ATP7A CYP7B1 STAT1 PGM1 APC TNPO3